Trial NCT01702558

View at ClinicalTrials.gov 
Org. Study IDs: MO28230
Secondary IDs: 2012-001547-46

Last trial update was posted on 2021-01-22

MeSH Interventions

Ado-Trastuzumab Emtansine Capecitabine Maytansine Trastuzumab

MeSH Conditions

Breast Neoplasms Stomach Neoplasms

Other Conditions

Breast Cancer Gastric Cancer

Stopping Reasons

The sponsor decided to terminate study after 70% of participants had experienced a progression-free survival event.

Limitations And Caveats

The sponsor decided to terminate the study after 70% of participants had experienced a PFS event. Participants were allowed to continue treatment by enrolling into study NCT00781612 or by moving to commercial drug, depending on their country.

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID